Odonate (Odonate) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Odonate Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Odonate is: No Data: Cannot be evaluated.

Competitive Comparison of Odonate's Risk Assessment

For the Shell Companies subindustry, Odonate's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Odonate's Risk Assessment Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Odonate's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Odonate's Risk Assessment falls into.

Odonate (OTCPK:ODTC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Odonate Risk Assessment Related Terms

Thank you for viewing the detailed overview of Odonate's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Odonate (Odonate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 East 28th Street, 10th Floor, New York, NY, USA, 10016

Website

https://www.odonate.com

Odonate Inc is a Shell company.

Executives

Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang	director, 10 percent owner, officer: Chief Executive Officer	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell	officer: Chief Medical Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121